Treatment Approach in MG

Opinion
Video

Expert neurologists discuss the factors that guide treatment selection in MG, shifting the framework to take patient preferences into account.

This is a video synopsis/summary of a panel discussion involving James Howard, MD; Nicholas Silvestri, MD, FAAN; Tuan Vu, MD; Ali Habib, MD; and Beth Stein, MD.

The landscape of myasthenia gravis (MG) treatment has evolved significantly, with a proliferation of new therapies marking what some consider the "golden years" for the disease. Over the past 15 years, the approval of the first-ever drug for MG has spurred pharmaceutical interest in the condition. This interest stems from the disease's status as a prototypical autoimmune disorder, making it an attractive starting point for therapeutic development.

In this rapidly changing treatment landscape, physicians are shifting their focus towards patient-centered care, prioritizing individual patient needs and preferences. Factors such as serology, rate of disease progression, comorbidities, and disease severity still inform treatment decisions, but patient preference now plays a more significant role.

The trend in treatment selection is moving away from broad-spectrum immunosuppressants towards targeted therapies that offer quicker onset of action and fewer side effects. The goal of treatment is no longer just symptom alleviation but achieving minimal symptoms with minimal or no adverse events, aligning with patients' desires for improved quality of life.

As the treatment paradigm shifts, there's a growing emphasis on engaging patients in shared decision-making to strike a balance between clinical expectations and patient preferences. Newer therapies offer the potential for more effective symptom management with a faster onset of action and fewer adverse events, setting higher expectations for treatment outcomes and reshaping the conversation around MG management.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.

Related Videos
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
© 2024 MJH Life Sciences

All rights reserved.